Micron's Chief Business Officer, Sumit Sadana, recently said that it was "sold out" of memory for 2026 -- and that was before ...

The stock reached $19 per share last October, but today it is 63% below its 52-week high. With shares trading under $9 a ...

Usually, investors need to see much higher growth to justify this valuation level. Despite Costco's strong digital sales ...

While these deals strengthen Palo Alto's positioning in the cybersecurity space and expand on its platformization strategy, ...

Even though revenue is under $20 million today, there is a scenario in which AST SpaceMobile generates $1 billion or more in ...

Enbridge ( ENB 0.21%) has an elite track record. The Canadian pipeline and utility company has increased its dividend for 31 ...

Through 2030, ExxonMobil expects double-digit earnings and cash flow growth, even at mediocre oil prices. Relentless buybacks ...

Novartis ( NVS 0.66%) is a major Swiss drug company with a market capitalization of over $300 billion. Its focus areas are ...

Fiserv missed on the bottom line in a major way in the third quarter, and its stock plunged. It recently got a new CEO who's developing a plan to embed more AI in the business and meet consumer needs.

Vertex Pharmaceuticals' market-beating returns over the past 10 years wouldn't have been enough to turn $100,000 into $1 million. Though it still has strong prospects, this goal seems far too ...

The Direxion Daily Financial Bear 3X Shares is still useful for some traders, but don't expect it to act like 2008 is back.